# US 2012/0252691 A1 · Modified nucleotides methods and kits

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252691 A1
- Document ID: US20120252691A1
- Status: Published application
- Kind: A1
- Application number: 13/482,927
- Filed: 2012-05-29
- Published: 2012-10-04
- Earliest claimed: 2010-04-21
- Assignees: Pierce Biotechnology, Inc.
- Inventors: Christopher L. Etienne; Kay K. Opperman; Barbara J. Kaboord; Scott Meier; Jean-Samuel Schultz
- Web page: https://patentgrep.com/patent/US20120252691A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C07H 19/10: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- C12Y 605/01001: DNA ligase (ATP) (6.5.1.1)
- C12Y 605/01002: DNA ligase (NAD+) (6.5.1.2)
- C12Y 605/01003: RNA ligase (ATP) (6.5.1.3)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

Modified nucleotides, and methods to modify nucleotides with a moiety or label, such as biotin, that permits their detection and results in a modified nucleotide, and methods of use of the modified nucleotide in quantitative and qualitative assays.

## Claims

### Claim 1

A compound having the structure (I):
where each of P1 and P2 is a phosphate group; Nus is a nucleoside moiety containing a sugar bound to a purine or pyrimidine base; Alk is a connecting group having the structure -//-(CH2)m—Y-//- where Y is a bond or bond forming group selected from
and m is an integer ranging from 3 to 6 inclusive;
Lnk is a linking group having the structure
where n is an integer ranging from 2 to 48 inclusive;
A1 is a bond forming group selected from
A2 is a bond forming group selected from
A3, when present, is a bond forming group selected from
X is a cleavable group that can undergo silicon-carbon cleavage, nucleophilic cleavage, redox cleavage, photochemical cleavage, enzymatic cleavage, or exchange-based cleavage,
Z is a branching group that contains a modifying molecule (Mod)
Mod is a modifier or modifying molecule
and
Obs is an observable label moiety.

### Claim 2 (depends on 1)

The compound of claim 1 where
the sugar is ribose having a 5′ site, a 3′ site, and a 1′ site,
P1 is attached to ribose at the 5′ site, P2 is attached to ribose at the 3′ site,
and the purine or pyrimidine base is selected from cytosine (C), uracil (U), adenine (A), guanine (G), or inosine (I) and is attached to ribose at the 1′ site.

### Claim 3 (depends on 1)

The compound of claim 1 where the purine or pyridine base is selected from 1-methyladenine, N6-methyladenine, N6-isopentyladenine, N,N-dimethyladenine, 7-deazaadenine, 2-thiocytosine, 3-methylcytosine, N4-acetylcytosine, 2-thiocytosine, 1-methylguanine, 2-methylguanine, 7-methylguanine, N2,N2-dimethylguanine, 7-deazaguanine, 2-thiouracil, 6-thiopurine, or 2,6-diaminopurine.

### Claim 4 (depends on 1)

The compound of claim 1 where the observable label is a chromogen, a fluorophore, a mass label, a spin label, a streptavidin-binding label, or a secondary detection label.

### Claim 5 (depends on 1)

The compound of claim 1 where n is an integer ranging from 2 to 24 inclusive.

### Claim 6 (depends on 1)

The compound of claim 1 where the sugar is ribose; the purine or pyrimidine base is selected from adenine (A), cytosine (C), guanine (G), uracil (U), or inosine (I); m is 3; n is 4; and the observable label is a streptavidin-binding compound selected from biotin, desthiobiotin, or iminobiotin.

### Claim 7 (depends on 1)

The compound of claim 1 where the sugar is ribose; the purine or pyrimidine base is cytosine (C); m is 3; Lnk is
where
n is 4, A1 is
A2 is
when present Z is a branching group that contains a modifying molecule (Mod), and when present A3 is
Mod is a modifier or modifying molecule, and
Obs is selected from the group consisting of biotin, a fluorophore, and an azide.

### Claim 8

A compound having the structure (II):
or a salt, conjugate base, tautomer, or ionized form thereof, where
Base* is a purine or pyrimidine base;
R is H, OH, CH3, or a hydroxyl protecting group;
Alk is a connecting group having the structure -//-(CH2)m—Y-//- wherein m is an integer ranging from 3 to 6 inclusive, Y is a bond forming group selected from
and
the leftmost bond is to Base* and the rightmost bond is to Lnk;
Lnk is a linking group having the structure
where n is an integer ranging from 2 to 48 inclusive,
A1 is a bond forming group selected from
A2 is a bond forming group selected from
A3 is a bond forming group selected from
and X is a cleavable group that can undergo silicon-carbon cleavage, nucleophilic cleavage, redox cleavage, photochemical cleavage, enzymatic cleavage, or exchange-based cleavage;
Z is a branching group that contains a modifying molecule (Mod); and
the leftmost bond is to Alk and the rightmost bond is to Obs; and
Obs is an observable label moiety.

### Claim 9 (depends on 8)

The compound of claim 8 where the sugar is ribose, and the purine or pyrimidine base is selected from cytosine (C), uracil (U), adenine (A), guanine (G), or inosine (I).

### Claim 10 (depends on 9)

The compound of claim 9 where the purine or pyridine base is selected from 1-methyladenine, N6-methyladenine, N6-isopentyladenine, N,N-dimethyladenine, 7-deazaadenine, 2-thiocytosine, 3-methylcytosine, N4-acetylcytosine, 2-thiocytosine, 1-methylguanine, 2-methylguanine, 7-methylguanine, N2,N2-dimethylguanine, 7-deazaguanine, 2-thiouracil, 6-thiopurine, or 2,6-diaminopurine.

### Claim 11 (depends on 8)

The compound of claim 8 where the observable label is a chromogen, a fluorophore, a mass label, a spin label, a streptavidin-binding label, or a secondary detection label.

### Claim 12 (depends on 8)

The compound of claim 8 where n is an integer selected from 2 to 24 inclusive.

### Claim 13 (depends on 8)

The compound of claim 8 where the sugar is ribose; the purine or pyrimidine base is selected from adenine (A), cytosine (C), guanine (G), uracil U), or inosine (I); m is 3; n is 4; and the observable label is a streptavidin-binding compound selected from biotin, desthiobiotin, or iminobiotin.

### Claim 14 (depends on 8)

The compound of claim 8 where the sugar is ribose; the purine or pyrimidine base is cytosine (C); m is 3; Lnk is
where
n is 4, A1 is
A2 is
and when present, A3 is
and
Z is a branching group that contains a modifying molecule (Mod), and Obs is selected from the group consisting of biotin, a fluorophore, and an azide.

### Claim 15 (depends on 1)

The compound of any of claim 1 including a salt, conjugate base, tautomer, and/or ionized form of the compound.

### Claim 16 (depends on 1)

A method for enriching for an RNA-binding protein or RNA binding complex utilizing the modified RNA labeled as in claim 1 as bait.

### Claim 17 (depends on 16)

The method of claim 16 where the RNA is labeled by contacting the RNA with an excess of modified ribonucleotide containing an affinity handle using T4 RNA ligase.

### Claim 18 (depends on 17)

The method of claim 17 further including a crosslinking agent to the excess of modified ribonucleotide containing an affinity handle.

### Claim 19 (depends on 17)

The method of claim 17 where the affinity handle is selected from at least one of biotin-PEG4-alkane-3′5′-bisphosphate cytidine; desbiotin-PEG4-alkane-3′5′-bisphosphate cytidine, biotin-PEG12-alkane-3′5′-bisphosphate cytidine; desbiotin-PEG12-alkane-3′5′-bisphosphate cytidine; azido-PEG4-alkane-3′5′-bisphosphate cytidine; azido-PEG12-alkane-3′5′-bisphosphate cytidine; TMT-PEG4-alkane-3′5′-bisphosphate cytidine; and/or TMT-PEG12-alkane-3′5′-bisphosphate cytidine.

### Claim 20 (depends on 16)

The method of claim 16 where the protein source is at least one of cell lysate, tissue lysate, exogenously expressed protein in cell or tissue lysates, protein expressed in an in vitro transcription and/or translation system, and/or protein purified form bacteria, yeast, fungi, tissue, or mammalian cells.

### Claim 21 (depends on 20)

The method of claim 20 where the labeled RNA is contacted with the protein lysate and affinity resin or matrix in an optimized binding buffer.

### Claim 22 (depends on 21)

The method of claim 21 further comprising washing, eluting, and detecting the RNA protein complex.

### Claim 23 (depends on 22)

The method of claim 22 where detection is by Western blot, array, and/or mass spectrometry.

### Claim 24 (depends on 1)

A method for enriching for an RNA binding protein or RNA binding protein complex using the labeled RNA of claim 1 containing a crosslinker within the ligated modified nucleotide, the crosslinker attached to the RNA using T4 RNA ligase.

### Claim 25 (depends on 1)

A method for enriching for an RNA binding protein or RNA binding protein complex using the labeled RNA of claim 1 containing a crosslinker cleavable within the ligated modified nucleotide that is attached to the RNA using T4 RNA ligase.

### Claim 26 (depends on 1)

A method for enriching for an RNA binding protein or RNA binding protein complex using the labeled RNA of claim 1 that further includes a crosslinking reagent.

### Claim 27 (depends on 16)

The method of claim 16 using an affinity matrix, where the affinity matrix is streptavidin agarose resin, streptavidin magnetic breads, hydrazide resin, alkoxyamine resin, modified agarose resin, soft-release streptavidin magnetic beads, soft-release agarose resin, and/or resin coupled with at least one anti-tandem mass tag (TMT) antibody.

### Claim 28 (depends on 1)

A kit for enriching an RNA binding protein or RNA binding protein complex, the kit comprising reagents for labeling the RNA of claim 1.

### Claim 29 (depends on 28)

The kit of claim 28 where the reagents are optimized for efficient enrichment of the RNA binding protein or RNA binding protein complex.

### Claim 30 (depends on 28)

The kit of claim 28 further comprising at least one positive control and at least one negative control.

### Claim 31 (depends on 6)

A kit where for enriching an RNA binding protein or RNA binding protein complex, the kit comprising reagents for labeling the RNA of claim 6 containing a modified RNA with a crosslinker, such that the labeled RNA contains an affinity handle and crosslinking reagent.

### Claim 32

A synthetic method for producing a trifunctional synthesis of modified ribonucleotide.

### Claim 33

A kit comprising a set of reagents for both in vivo and in vitro capture and detection of RNA-protein interactions.
